BMS Archive

Plant · Scientific monograph

Harpagophytum procumbens

Devil's claw

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Musculoskeletal research, Traditional herbal use

Research overview

Historical use

Devil's claw secondary root is used in traditional herbal preparations; EMA assessment distinguishes root preparations and does not find a sufficient basis for well-established efficacy [3].

Modern research context

A systematic review of 12 trials found that the evidence varied by preparation and harpagoside content, with heterogeneity limiting pooling [1]. A 60-person trial compared a named product with meloxicam over unequal treatment periods; it found no significant superiority between groups [2]. These findings are product- and indication-specific.

Adverse effects

Adverse-event evidence varies by formulation and trial; available sources do not establish long-term safety across powders and extracts [1-3].

Contraindications

EMA does not establish well-established use. Avoid generalizing findings among powdered root, aqueous extract and ethanolic extracts [1-3].

Clinical and phytochemical data

Used part

Secondary roots/tubers; human trials used specific powder or extract preparations and are not interchangeable [1-3].

Primary active compounds

  • Harpagoside is used to characterize some preparations; amount varies by product [1,3].

Mechanism of action

Clinical studies do not establish a single validated human mechanism for the diverse preparations [1,2].

Pharmacokinetics

Absorption

No general human PK profile identified across the distinct devil's-claw preparations [1-3].

Distribution

Not characterized.

Metabolism

Not characterized.

Excretion

Not characterized.

Safety and interactions

Drug interactions

No comprehensive clinical interaction profile established by the cited sources.

Toxicity

Safety evidence is formulation-specific; trial heterogeneity and short follow-up limit conclusions [1,2].

Special precautions

Pregnancy

Medicinal-use safety in pregnancy is not established by the cited trials.

Lactation

Lactation safety is not established.

Hepatic impairment

No impairment-specific evidence identified; product labeling and clinician review are appropriate where underlying disease is present.

Renal impairment

No impairment-specific evidence identified.

Sources and references

  1. [1] Joel J. Gagnier, Sigrun Chrubasik, Eric Manheimer. Harpagophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complementary and Alternative Medicine. 2004;4:13. PMID: 15369596. DOI: 10.1186/1472-6882-4-13.
  2. [2] Hamid Reza Farpour et al. The Efficacy of Harpagophytum procumbens (Teltonal) in Patients with Knee Osteoarthritis: A Randomized Active-Controlled Clinical Trial. Evidence-Based Complementary and Alternative Medicine. 2021;2021:5596892. PMID: 34712343. DOI: 10.1155/2021/5596892.
  3. [3] EMA/HMPC. Assessment report on Harpagophytum procumbens and/or H. zeyheri, radix.

Additional source links

Continue browsing